Discover mAbs About Us Research Media Center Get Involved
The Science Behind Protection

Understanding Monoclonal Antibodies

Discover how mAbs work at the molecular level to provide immediate, targeted protection against infectious diseases — bridging the gap between exposure and immunity.

Foundation
What Are Monoclonal Antibodies?
mAbs are laboratory-produced versions of the antibodies your immune system naturally creates to fight off infections.

Think of antibodies as your body's molecular security force. Each antibody is shaped like a Y, with two identical arms that can grab onto specific parts of a virus or bacterium — like a key fitting into a lock.

When your immune system encounters a threat, it produces millions of different antibodies. Scientists can isolate the most effective ones, clone them in the lab, and produce identical copies at scale.

The result: A targeted therapy that delivers the exact antibodies you need, when you need them — without waiting for your immune system to figure it out.

Unlike vaccines that teach your body to make antibodies, mAbs provide ready-made protection that works immediately upon administration.

Antigen Binding Sites (Fab) Fc Region
Antibody Structure
Y-shaped protein with two antigen-binding sites and one Fc region for immune signaling
The Process
How They Work: 4-Step Protection
From identification to protection — the complete mAb pathway explained.
1

Identify Target

Scientists analyze viral structure to find the best binding sites — usually proteins the virus uses to enter cells.

2

Engineer Solution

Antibodies are designed and optimized in the lab, then produced at scale using specialized cell cultures.

3

Administer Therapy

mAbs are delivered via injection, typically intramuscular, where they enter circulation immediately.

4

Neutralize & Protect

Antibodies bind to the virus, blocking infection and flagging pathogens for immune system cleanup.

Understanding the Difference
mAbs vs Traditional Approaches
How monoclonal antibodies compare to vaccines and other preventive measures.

Characteristic

Monoclonal Antibodies

Traditional Vaccines

Speed of Protection
Immediate (hours)
× Delayed (2-4 weeks)
Immune System Requirement
Works regardless
× Requires functional immunity
Effectiveness in Elderly/Immunocompromised
High efficacy
× Reduced response
Adaptation to Variants
Rapid (weeks)
× Slower (months)
Use for Treatment
Prevention & treatment
× Prevention only
Duration of Protection
3-6 months single dose
Variable, often longer
Applications
Diseases & Conditions
mAbs are being developed and deployed across a wide range of infectious diseases and immune challenges.

Respiratory Syncytial Virus

FDA Approved

85% effectiveness in preventing severe RSV in infants. Nirsevimab (Beyfortus) provides season-long protection.

COVID-19

Multiple Approved

Several mAbs authorized for treatment and prevention, especially for immunocompromised populations.

Seasonal Influenza

In Development

Broad-spectrum antibodies targeting conserved flu proteins show promise across multiple strains.

Ebola Virus

FDA Approved

Inmazeb combination therapy dramatically improves survival rates in Ebola patients.

HIV Prevention

Phase III Trials

Long-acting antibodies showing promise as PrEP alternative with potential 6-month dosing.

Malaria Prevention

Clinical Success

CIS43LS provides season-long protection from single injection, extending mAb paradigm to parasitic diseases.

Bacterial Infections

Emerging Field

New approaches to multidrug-resistant bacteria including C. difficile and Pseudomonas aeruginosa.

Cancer Immunotherapy

Multiple Approved

Checkpoint inhibitors and targeted therapies revolutionizing cancer treatment across many types.

Ready to explore the evidence behind this revolutionary approach to disease prevention?

View Research →